• Medientyp: E-Artikel
  • Titel: Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
  • Beteiligte: Wöckel, Achim; Festl, Jasmin; Stüber, Tanja; Brust, Katharina; Krockenberger, Mathias; Heuschmann, Peter; Jírů-Hillmann, Steffi; Albert, Ute-Susann; Budach, Wilfried; Follmann, Markus; Janni, Wolfgang; Kopp, Ina; Kreienberg, Rolf; Kühn, Thorsten; Langer, Thomas; Nothacker, Monika; Scharl, Anton; Schreer, Ingrid; Link, Hartmut; Engel, Jutta; Fehm, Tanja; Weis, Joachim; Welt, Anja; Steckelberg, Anke; [...]
  • Erschienen: Georg Thieme Verlag KG, 2018
  • Erschienen in: Geburtshilfe und Frauenheilkunde
  • Sprache: Deutsch
  • DOI: 10.1055/a-0646-4630
  • ISSN: 0016-5751; 1438-8804
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p> Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer.</jats:p><jats:p> Method The process of updating the S3 guideline published in 2012 was based on the adaptation of identified source guidelines. They were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and with the results of a systematic search of literature databases followed by the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point and used them to develop suggestions for recommendations and statements, which were then modified and graded in a structured consensus process procedure.</jats:p><jats:p> Recommendations Part 2 of this short version of the guideline presents recommendations for the therapy of primary, recurrent and metastatic breast cancer. Loco-regional therapies are de-escalated in the current guideline. In addition to reducing the safety margins for surgical procedures, the guideline also recommends reducing the radicality of axillary surgery. The choice and extent of systemic therapy depends on the respective tumor biology. New substances are becoming available, particularly to treat metastatic breast cancer.</jats:p>
  • Zugangsstatus: Freier Zugang